Mission

Bringing Transformational Medicines
to Patients Through Innovation

Values

Innovation
Integrity
Resilience

Highlights

  • 9

    Innovative Clinical Assets

  • >20

    BD Transactions

  • $1.8B

    Total Deal Value

  • 300+

    Issued Patents &
    Patent Applications

  • 60%

    Employees
    with Advanced Degrees

Global Footprint

Awards

2022

Top 30 Innovative Antibody Biotech in China

MeNet

2022

Top Rankings in Five Categories
including Honored Companies, etc.

Institutional Investor

2021

Entrepreneur of the Year

EY

2021

Executive of the Year

Scrip Awards

2021 Company of the Year

2020 Deal of the Year

BioCentury, BayHelix

2021

Excellent Employer

T+Employer™

2021

Leading DEI X Inclusion Award

sHero

2021

Top 50 Enterprises of Technology Power

Tech Power

2020

China Healthcare New Power Top 10

people.cn

2020

50 Smartest Companies

MIT Technology Review

2020

Top 10 China Biotech to Watch

FiercePharma

2019

Top 10 Immuno-Oncology Startups

GEN

* The manufacturing facility is managed by I-Mab Hangzhou entity.